Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life (HRQL) · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).
1 finding from 1 review
Global improvement (Asafoetida subgroup) · people with irritable bowel syndrome
It is very uncertain whether homeopathy changes global improvement (Asafoetida subgroup) compared with placebo (very low certainty).
1 finding from 1 review
Global improvement (Asafoetida + nux vom subgroup) · people with irritable bowel syndrome
It is very uncertain whether homeopathy changes global improvement (Asafoetida + nux vom subgroup) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of defecation (mean number of bowel movements per week) · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stool consistency · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in endoscopic relapse compared with placebo (low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgical relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review